C1332828||cytochrome P450 2C19
C0678941||Variants
C0070166||Clopidogrel
C1532338||Percutaneous Coronary Intervention
C4277630||pharmacogenetic variants
C0960580||cytochrome P450 2C19
C0960580||cytochrome P450 2C19
C0070166||clopidogrel
C0302106||platelet inhibition
C1155266||inflammatory response
C1532338||percutaneous coronary intervention
C1532338||percutaneous coronary intervention
C0920267||residual platelet aggregation rate
C0920267||residual platelet aggregation rate
C0427425||plasma levels
C2825885||sCD40L
C3890352||sP-selectin
C0165519||MMP-9
C0078056||sVCAM-1
C3890402||sE-selectin
C1532338||percutaneous coronary intervention
C0332293||treated with
C0070166||clopidogrel
C1522577||followed up
C1707181||CYP2C19(*)2
C1707182||(*)3
C0678941||variants
C0070166||clopidogrel
C1517481||gene detection kit
C0243095||higher RPA
C0115305||sE-selectin
C0167627||sCD40L
C0134835||sP-selectin
C0165519||MMP-9
C0078056||sVCAM-1
C3203684||CYP2C19 intermediate metabolizer
C1707180||CYP2C19(*)1
C1707181||(*)2
C1707180||(*)1
C1707182||(*)3
C1707181||CYP2C19(*)2
C1707181||(*)2
C1707181||(*)2
C1707182||(*)3
C1707182||(*)3
C1707182||(*)3
C0243095||IM+PM groups
C1707180||CYP2C19(*)1
C1707180||/(*)1
C1522577||follow-up
C1273410||risk of MACE
C0243095||CYP2C19 IM+PM
C1332828||cytochrome P450 2C19
C1707181||CYP2C19(*)2
C1707182||(*)3
C0678941||variants
C0070166||clopidogrel
C1532338||percutaneous coronary intervention
C1273410||risk of MACE
C1332828||cytochrome P450 2C19
C4277630||pharmacogenetic profiling
C1532338||percutaneous coronary intervention
C0070166||clopidogrel
C0087111||treatment
C0070166||clopidogrel